PARP inhibitor

Lynparza® (olaparib) tablets receive approval as maintenance therapy treatment for ovarian cancer regardless of BRCA status

Retrieved on: 
Tuesday, May 8, 2018
Cancer, Breast cancer, Ovarian cancer, RTT, Hereditary cancers, Gynaecology, BRCA mutation, PARP inhibitor, BRCA, High-grade serous carcinoma, Rucaparib

Approximately 25 per cent of Canadian women with this type of ovarian cancer have an abnormality in their BRCA genes, and 75 per cent are wild type (non-mutated).viii

Key Points: 
  • Approximately 25 per cent of Canadian women with this type of ovarian cancer have an abnormality in their BRCA genes, and 75 per cent are wild type (non-mutated).viii
    "For women with ovarian cancer, few treatments have become publicly available for many years.
  • "This approval is good news, albeit an early step, along the way to opening up treatment options for a broader group of women with ovarian cancer, regardless of their BRCA status.
  • ix It is the first PARP inhibitor to be approved as a maintenance therapy for patients with platinum-sensitive relapsed ovarian cancer regardless of BRCA status.
  • Women already diagnosed with BRCA-mutated or high-grade ovarian cancer should speak to their doctor about new treatment options available to them.